ERBB2 and breast cancer: Although HER2-targeted therapies (Trastuzumab, Lapatinib) have greatly improved management of this malignancy, there is a significant rate of primary and acquired resistance3,4, urging to identify additional factors that contribute to HER2+ BC pathogenesis and survivorship.